# Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

> **NCT02372578** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 115 (actual)

## Conditions studied

- Painful Diabetic Peripheral Neuropathy (PDPN)

## Interventions

- **DRUG:** ASP3662
- **DRUG:** pregabalin
- **DRUG:** ASP3662 placebo
- **DRUG:** pregabalin placebo

## Key facts

- **NCT ID:** NCT02372578
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-27
- **Primary completion:** 2016-05-20
- **Final completion:** 2016-05-20
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** The study was terminated due to futility analysis.
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372578, "Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02372578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*